Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
Costs of hemophilia A treatment are increasing. Waste of clotting products should be avoided. To estimate the first-year waste of emicizumab prophylaxis for people with hemophilia A and inhibitors (PwHAi) who failed immune tolerance induction (ITI), in Brazil. We evaluated the manufacturer and the B...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer
2023-12-01
|
| coleção: | Saudi Pharmaceutical Journal |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S1319016423003626 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|